louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03483402: Micropulse Laser Trabeculoplasty as Adjunctive Treatment in Patients With Pseudoexfoliation Glaucoma
Official title: Study of the Efficacy of a Single Session Micropulse Laser Trabeculoplasty as an Adjunctive Measure in Decreasing Intraocular Pressure in Patients Suffering From Pseudoexfoliation Glaucoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pseudoexfoliation Glaucoma
Primary Open-angle Glaucoma
Keywords: Pseudoexfoliation Glaucoma
Primary Open-angle Glaucoma
Micropulse Laser Trabeculoplasty
Intraocular Pressure
Lead sponsor: University Hospital of Patras
Sponsor class: OTHER
First posted: 2018-03-30
Enrollment: 27
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Single-center, one-arm, prospective clinical trial.
Primary purpose: TREATMENT

Brief summary: This study aims to evaluate the effect of a single session of micropulse laser trabeculoplasty (MLT) on cornea in eyes with primary open glaucoma (POAG) and pseudoexfoliation glaucoma (PEXG).

Detailed description: Patients with PEXG under prostaglandine analogue monotherapy with inadequate IOP control are treated with 360-degrees 532nm MLT.

Patients are evaluated at 1 day, 1 month, 3 months, 6 months and 12 months post-MLT. After trabeculoplasty patients are maintained in treatment with the same drug regimen as pre-MLT.

Eligibility criteria: Inclusion Criteria:

* Patients with POAG or PEXG under treatment with glaucoma agents requiring additional reduction of IOP, age older than 18 years, patients willing to provide informed consent to participate in the study and to adhere to the follow-up schedule.

Exclusion Criteria:

* pre-existing corneal pathology or scar, history of any previous ocular surgery or any planned ocular surgery during the study, history of prior laser trabeculoplasty, end-stage glaucoma with advanced visual field defect, monocular patients, history of trauma, and concurrent systemic or topical steroid use
* patients unable to present for follow up

Primary outcomes:
measure: Intraocular Pressure
timeFrame: 12 months
Secondary outcomes:
measure: Intraocular Pressure
timeFrame: 1, 3 and 6 months
Other outcomes:
Locations:
Study officials:
affiliation: University of Patras, Medical School
name: Constantine D Georgakopoulos, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Makri OE, Pallikari A, Pagoulatos D, Kagkelaris K, Kostopoulou EV, Georgakopoulos CD. Micropulse laser trabeculoplasty on pseuodexfoliation glaucoma patients under topical prostaglandin analogue monotherapy: 1-year results. Graefes Arch Clin Exp Ophthalmol. 2019 Feb;257(2):349-355. doi: 10.1007/s00417-018-4195-2. Epub 2018 Nov 28.
Clinical trial NCT05800002: IVUS-guided DES Implantation in Coronary Calcification
Official title: Intravascular Ultrasound Versus Angiography Guided Drug-eluting Stent Implantation for Patients With Coronary Severe Calcification: a Prospective, Multicenter, Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Coronary Artery Disease
Lead sponsor: Nanjing First Hospital, Nanjing Medical University
Sponsor class: OTHER
First posted: 2023-04-05
Enrollment: 864
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Coronary calcified lesion is associated with a poor clinical outcome. Intravascular ultrasound (IVUS) provides anatomic information in detail about reference vessel dimensions and lesion characteristics including severity of diameter stenosis, lesion length, and morphology. Both randomized and observational studies have reported the clinical benefits of IVUS guidance for patients with chronic total occlusion (CTO), long lesions, acute coronary syndrome (ACS) with complex bifurcation lesions. Our previous ULTIMATE trial has demonstrated that IVUS-guided drug-eluting stent (DES) implantation significantly improved clinical outcome in all-comers, particularly for patients who had an IVUS-defined optimal procedure, compared with angiography guidance. However, the benefit of IVUS guidance in coronary severe calcification still remains unknown in the modern DES era.


Eligibility criteria: Inclusion Criteria:

1. Silent ischemia, stable or unstable angina, non-ST-segment elevation myocardial infarction \> 48 hours, or ST-segment elevation myocardial infarction \> 7 days;
2. De novo coronary lesion eligible for drug-eluting stent implantation;
3. Target lesion with severe calcification;

Exclusion Criteria:

1. Age less than 18-year-old;
2. Comorbidity with a life expectancy \<12 months;
3. Intolerant of antithrombotic therapy;
4. Significant anemia, thrombocytopenia, or leucopenia;
5. History of major hemorrhage (intracranial, gastrointestinal, and so on);
6. Chronic total occlusion lesion not recanalized;
7. Scheduled major surgery in the next 12 months;
8. Left ventricular ejection fraction \< 25%;
9. Uremia dependent on dialysis treatment;
10. Previous drug-eluting stent implantation in target vessel;

Primary outcomes:
measure: the rate of target-vessel failure at 12 months
timeFrame: 12 months after indexed procedure
Secondary outcomes:
Other outcomes:
Locations:
city: Nanjing
country: China
facility: Nanjing First Hospital
state: Jiangsu
Study officials:
affiliation: The First Affiliated Hospital with Nanjing Medical University
name: Shao-Liang Chen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01697202: Fatigue in Rheumatoid Arthritis - Longitudinal Study
Official title: Fatigue in Rheumatoid Arthritis - Longitudinal Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Fatigue
Rheumatoid Arthritis
Lead sponsor: Göteborg University
Sponsor class: OTHER
First posted: 2012-10-02
Enrollment: 67
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Persons with RA at the Rheumatology clinic at Sahlgrenska University hospital Gothenburg, Sweden

Brief summary: To investigate how the fatigue vary over time in persons with rheumatoid arthritis (RA) and which factors that may influence the fatigue.


Eligibility criteria: Inclusion Criteria:

* Diagnose of RA, age 20-65 years,

Exclusion Criteria:

* other serious physical or mental illness

Primary outcomes:
measure: Fatigue
timeFrame: 4 times during the course of the study up to one year
Secondary outcomes:
measure: Pain
timeFrame: 4 times during the course of the study up to one year
measure: Activity limitations
timeFrame: 4 times during the course of the study up to one year
measure: Disease activity
timeFrame: 4 times during the course of the study up to one year
measure: Health related quality of life
timeFrame: 4 times during the course of the study upto one year
Other outcomes:
Locations:
city: Göteborg
country: Sweden
facility: Sahlgrenska University Hospital
Study officials:
References:
Clinical trial NCT00875602: Evaluation of EverOn™ - A Contact-Free System for Measuring Heart Rate, Respiratory Rate and Motion
Official title: Evaluation of EverOn™ - A Contact-Free System for Measuring Heart Rate, Respiratory Rate and Motion
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Post Surgical Pat., Medical Pat., Resp. Failure, Car.Arrest, Death
Keywords: All hospitalized patients in a general Med/ Surg unit
Lead sponsor: EarlySense Ltd.
Sponsor class: INDUSTRY
First posted: 2009-04-03
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Evaluation of continuous monitoring device on patients Risk during hospitalization and nurse satisfaction level.

Detailed description: To assess the effects of continuous patient monitoring using a contactless monitor in a medical-surgical unit on transfers and length of stay at higher level of care units

Eligibility criteria: Inclusion Criteria:

* Hospitalized patients

Exclusion Criteria:

* None

Primary outcomes:
measure: Evidence of benefit to caregivers and patients
timeFrame: 12 month
Secondary outcomes:
Other outcomes:
Locations:
city: Los Angeles
country: United States
facility: CHMC
state: California
Study officials:
affiliation: CHW
name: Harvey V Brown, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04676802: Pain Relief After Trapeziectomy: Ibuprofen & Acetaminophen Versus Oxycodone
Official title: Pain Relief After Trapeziectomy Without Opioids: Ibuprofen & Acetaminophen Versus Oxycodone
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE2
Conditions: Pain, Postoperative
Osteoarthritis Thumb
Lead sponsor: Stanford University
Sponsor class: OTHER
First posted: 2020-12-21
Enrollment: 121
Sex: ALL
Minimum age (years): 45
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: In the US, pain management after surgery for surgical treatment of osteoarthritis at the base of the thumb typically consists of prescription opioids during the early recovery phase. Given the highly addictive nature of prescription opioids, guidelines are being evaluated by hand surgeons to reduce opioid use while still maintaining pain control after surgery. A promising approach is to use non-narcotic medication as the first line of treatment. The purpose of this study is to demonstrate the efficacy of a combination of non-steroidal anti-inflammatory drugs (NSAIDs), ibuprofen and acetaminophen, in comparison to a morphine analogue substance (oxycodone) for pain management in the first 30 days after surgery.


Eligibility criteria: Inclusion Criteria:

* Undergoing trapeziectomy for thumb osteoarthritis

English proficient,

Exclusion Criteria:

* Pregnancy

Current use of opioids

Concurrent surgeries (ex. trapeziectomy combined with carpal tunnel release)

Inability to complete study forms (education, cognitive ability, mental status, medical status)

Allergy or intolerance to Ibuprofen, Acetaminophen and/or Oxycodone

Liver or kidney dysfunction, abnormal liver enzymes restricting use of acetaminophen or ibuprofen

History of chronic heart failure, upper gastrointestinal bleeding or coagulopathy

History of complex regional pain syndrome

Primary outcomes:
measure: Change of medication consumption and overall amount
timeFrame: Every day from the first day after surgery to 30 days post-op.
measure: Change of worst daily pain score measured over time
timeFrame: Every day from the first day after surgery to 30 days post-op.
measure: Change of least daily pain score measured over time
timeFrame: Every day from the first day after surgery to 30 days post-op.
measure: Change of average daily pain score measured over time
timeFrame: Every day from the first day after surgery to 30 days post-op.
Secondary outcomes:
measure: Change in Quick DASH scores over time
timeFrame: Baseline, Post-operative weeks 1, 3, 5, and 8
measure: Change in PROMIS-PI scores over time
timeFrame: Baseline, Post-operative weeks 1, 3, 5, and 8
Other outcomes:
Locations:
city: Redwood City
country: United States
facility: Stanford Health Care
state: California
city: Salt Lake City
country: United States
facility: University of Utah Health Care
state: Utah
Study officials:
affiliation: Stanford Orthopaedic Surgery
name: Amy Ladd, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06212102: Dydrogesterone Versus GnRH Antagonist in Poor Responders Undergoing Double Ovarian Stimulation
Official title: Dydrogesterone Versus GnRH Antagonist in Poor Responders Undergoing Double Ovarian Stimulation: A Randomized Controlled Non-inferiority Trial
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE2
Conditions: Infertility
Keywords: Infertility
IVF-ET
Poor ovarian responders
Double stimulation
Lead sponsor: Bedaya Hospital
Sponsor class: OTHER
First posted: 2024-01-18
Enrollment: 120
Sex: FEMALE
Minimum age (years): 35
Maximum age (years): 44
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this randomized controlled trial was to compare the efficacy and cost-effectiveness of using progestin with GnRH antagonist to prevent premature LH surge in poor responders undergoing double stimulation protocol.


Eligibility criteria: Inclusion Criteria:

Patients belonging to Poseidon group 4

Exclusion Criteria:

* PCOS
* Endometriosis
* History of recurrent abortion

Primary outcomes:
measure: Medications costs per retrieved oocyte
timeFrame: Ten to fifteen days after starting ovarian stimulation]
Secondary outcomes:
measure: Clinical pregnancy rate
timeFrame: 5 weeks after embryo transfer]
measure: Ongoing Pregnancy Rate
timeFrame: 18 weeks after embryo transfer]
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Bedaya Hospital
Study officials:
affiliation: Cairo University
name: Ismail Aboul Foutouh, Prof.
role: STUDY_CHAIR
References:
citation: Ubaldi FM, Capalbo A, Vaiarelli A, Cimadomo D, Colamaria S, Alviggi C, Trabucco E, Venturella R, Vajta G, Rienzi L. Follicular versus luteal phase ovarian stimulation during the same menstrual cycle (DuoStim) in a reduced ovarian reserve population results in a similar euploid blastocyst formation rate: new insight in ovarian reserve exploitation. Fertil Steril. 2016 Jun;105(6):1488-1495.e1. doi: 10.1016/j.fertnstert.2016.03.002. Epub 2016 Mar 25.
Clinical trial NCT05399602: The Role of Neurofilament Light (NfL) in Patients With Hydrocephalus
Official title: The Role of Neurofilament Light (NfL) in Management of Patients With Hydrocephalus: A Pilot Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Hydrocephalus
Brain Damage
General Anesthetics Toxicity
Keywords: Hydrocephalus
Brain biomarkers
Neurofilament Light Chain
General Anesthesia
Lead sponsor: University Hospital Hradec Kralove
Sponsor class: OTHER
First posted: 2022-06-01
Enrollment: 20
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Neurofilament Light Chain Protein (NfL) has been found by many studies as a sensitive biomarker of neuronal damage from several reasons, e.g. neurodegenerative diseases (Alzheimer's disease, Multiple Sclerosis, etc.), inflamation (HIV) or trauma. Its role as biomarker thus offers a possibility to predict and manage diseases associated with neuronal damage. Therefore our aim is to investigate the changes in level of NfL in hydrocephalus and to find its role in management of treatment in hydrocephalus.


Eligibility criteria: Inclusion Criteria:

* In group A:

  * Patients with diagnosed communicating hydrocephalus
  * MMSE \> 10 points
  * Absence of any structural laesion on MRI or CT
  * Accepted Informed consent
* In group B:

  * MMSE \> 10 points
  * Absence of any structural laesion on MRI or CT
  * Accepted Informed consent
  * Elective spinal surgery without affecting dural sac and the spinal cord
  * Surgery shorter than 120 minutes of lasting the general anesthesia

Exclusion Criteria:

* Non-communicating hydrocephalus
* Structural laesion on MRI or CT (tumour, contusion, aneurysm)
* MMSE \< 10 points
* Life-expectancy shorter than 1 year
* Pre-existing other type of demetia (m. Alzheimer, vascular dementia)
* Surgery lasting more than 120 minutes
* Blood loss more than 500 ml
* Opening of dural sac (liquororhea)
* Adverse events during general anestesia: MAP\<60 mm Hg more than 5 minutes, arythmia with need for farmacological treatment

Primary outcomes:
measure: Recruitment rate
timeFrame: 6 months
measure: Number of changes in valve settings
timeFrame: 3 months after surgery
Secondary outcomes:
measure: Correlation between NfL level and patient's clinical state
timeFrame: 3 months after surgery
Other outcomes:
measure: Influence of general anesthesia on the level of NfL
timeFrame: 24 hours before procedure (surgery) and 24 hours and 5 days after surgery
Locations:
city: Hradec Králové
country: Czechia
facility: University Hospital Hradec Kralove
Study officials:
affiliation: University Hospital Hradec Kralove
name: Miroslav Cihlo, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00431002: Provincial Roll-Out Bone Health Strategy
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Osteoporosis
Keywords: Exercise
Resistance training
Lead sponsor: University of British Columbia
Sponsor class: OTHER
First posted: 2007-02-02
Enrollment: 0
Sex: FEMALE
Minimum age (years): 65
Maximum age (years): 75
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The main purpose of this study is to investigate the effect of two different group-based exercise programs on fall risk (muscular strength and balance) and bone strength in older women aged over 65-75 years who have low bone mass. We are also trying to determine if once a week exercise is as effective on health outcomes as twice a week. We hypothesize that twice a week exercise will be more effective than once a week or sham exercise.


Eligibility criteria: Inclusion Criteria:

* inactive (less than twice weekly exercising) women aged 65-75 years old

Primary outcomes:
measure: Physiologic Profile Assessment (Fall Risk)
Secondary outcomes:
measure: Bone strength using peripheral quantitative computed tomography (pQCT)
Other outcomes:
Locations:
Study officials:
affiliation: University of British Columbia
name: K M Khan, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02180802: Parental Involvement Improves the Effect of Motivational Interviewing on Weight Loss in Obese Adolescents: A Randomized Controlled Trial Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity, Adolescent
Keywords: obese adolescents
BMI ≥ 95th percentile for age and gender
Lead sponsor: Qazvin University Of Medical Sciences
Sponsor class: OTHER
First posted: 2014-07-03
Enrollment: 408
Sex: ALL
Minimum age (years): 13
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Motivational interviewing (MI) has been shown to be an effective strategy in targeting obesity in adolescents and parental involvement has been associated with increased effectiveness. The aim of the study is to evaluate and compare the role of parental involvement in MI interventions for obese adolescents


Eligibility criteria: Inclusion Criteria:

* BMI equal or higher than 95th percentile for age and gender
* 13-18 years old

Exclusion Criteria:

* medication with weight gain as side effects
* diagnosed with having eating disorder
* pregnant
* clinical mental health conditions
* psychosis

Primary outcomes:
measure: changes in BMI
timeFrame: changes from baseline and 12 months follow-up
measure: Child Dietary Self-Efficacy
timeFrame: changes from baseline and 12 months follow-up
measure: Weight Efficacy Lifestyle
timeFrame: changes from baseline and 12 months follow-up
measure: Physical Exercise Self-efficacy
timeFrame: changes from baseline and 12 months follow-up
measure: changes in physical activity
timeFrame: changes from baseline and 12 months follow-up
measure: changes in dietary pattern
timeFrame: changes from baseline and 12 months follow-up
Secondary outcomes:
measure: Changes in blood cholesterol level
timeFrame: changes from baseline and 12 months follow-up
measure: changes in blood triglyceride level
timeFrame: changes from baseline and 12 months follow-up
measure: Changes in body fat percentage
timeFrame: changes from baseline and 12 months follow-up
Other outcomes:
Locations:
city: Qazvin
country: Iran, Islamic Republic of
facility: Outpatient Pediatric Clinic
Study officials:
References:
Clinical trial NCT01300702: Neuropathic in the Acute Post Operative Phase
Official title: Identification of Neuropathic Pain in the Acute Post Operative Phase Following Thoracotomy
Study type: OBSERVATIONAL
Overall status: TERMINATED
Conditions: Lung Cancer
Lead sponsor: Rigshospitalet, Denmark
Sponsor class: OTHER
Collaborators: name: Section for Surgical Pathophysiology
name: Section of Acute Pain Management and Palliative Medicine
name: Multidisciplinary Pain Centre
name: Innovative Medicines Initiative
First posted: 2011-02-23
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Lung cancer patients undergoing thoracotomy

Brief summary: Investigation of thermal thresholds and sensory mapping to thermal stimuli


Eligibility criteria: Inclusion Criteria:

* age \> 18 years old

Exclusion Criteria:

* do not under stand Danish
* cognitive reduction
* previous thoracic surgery
* Pregnant or nursing
* inability to cooperate to pain scoring

Primary outcomes:
measure: Pain
timeFrame: 14 days
measure: quantitative sensory testing (QST)
timeFrame: 14 days
measure: Neuropathic pain
timeFrame: 14 days
Secondary outcomes:
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Rigshospitalet
city: Copenhagen
country: Denmark
facility: Section for Surgical Pathophysiology 4074
Study officials:
affiliation: Section for Surgical Pathophysiology
name: Henrik Kehlet, MD
role: STUDY_CHAIR
affiliation: Section for Surgical Pathophysiology
name: Kim Wildgaard, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05693402: Opioid-Free Anesthesia in Modified Radical Mastectomy
Official title: Efficacy of Opioid-Free Anesthesia in Modified Radical Mastectomy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Surgery
Anesthesia
Opioid Use
Lead sponsor: Dr Etienne El Helou
Sponsor class: OTHER
First posted: 2023-01-23
Enrollment: 116
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Between January 2018 and September 2020, data from admitted patients for modified radical mastectomy under general anesthesia were enrolled.

Brief summary: The aim of this study is to evaluate the efficacy of opioid-free general anesthesia for breast surgeries in female patients.


Eligibility criteria: Inclusion Criteria:

* Patients underwenting modified radical mastectomy
* Undergoing general anesthesia

Exclusion Criteria:

* Patients were excluded if they had Alzheimer's Disease, mental retardation, failure of locoregional anesthesia, contraindication for locoregional anesthesia.

Primary outcomes:
measure: Post operative Morphone use
timeFrame: up to 24 hours
measure: Time To Extubation (TTE)
timeFrame: Directly intraOp
Secondary outcomes:
measure: Post Operative Nausea and Vomiting (PONV)
timeFrame: Up to 24hours
Other outcomes:
Locations:
city: Beirut
country: Lebanon
facility: Lebanese Hospital Geitaoui-University Medical Center
Study officials:
References: